Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended April 4, 2003 (referred to as March 31, 2003 for presentation), filed by Wilson Greatbatch Technologies, Inc. The company is a leading developer and manufacturer of batteries, capacitors, and components for implantable medical devices (Medical Technology segment) and high-performance batteries for commercial applications such as oil and gas exploration (Commercial Power Sources segment).
Key Financial Metrics
| Metric | Q1 2003 | Q1 2002 |
|---|---|---|
| Revenues | $54,857,000 | $36,303,000 |
| Gross Profit | $22,813,000 | $15,952,000 |
| Gross Margin | 42% | 44% |
| Operating Income | $9,747,000 | $5,756,000 |
| Net Income | $6,037,000 | $3,339,000 |
| Diluted EPS | $0.28 | $0.16 |
| Cash from Operations | $5,025,000 | $1,950,000 |
| Cash and Equivalents (End) | $2,203,000 | $37,551,000 |
| Total Debt (Current + Long-term) | $79,500,000 | $85,000,000 (approx) |
| Working Capital | $51,468,000 | $40,204,000 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 51% to $54.9 million, driven by a 58% surge in the Medical Technology segment and a 14% increase in Commercial Power Sources.
- Segment Performance: Medical components revenue doubled (102% increase) due to the inclusion of Greatbatch-Globe and higher demand for filtered feedthroughs. ICD battery revenue rose 65%.
- Profitability: Net income increased 81% to $6.0 million. However, gross margin declined 2.3 percentage points to 42%, attributed to lower margins from the Greatbatch-Globe acquisition and costs related to lean manufacturing initiatives.
- Cash Position: Cash and cash equivalents decreased significantly by $2.4 million to $2.2 million, primarily due to debt principal payments of $5.5 million and capital expenditures of $2.1 million.
- Debt Reduction: The company reduced its current portion of long-term debt from $8.75 million to $3.25 million.
Outlook, Commentary, and Risks
- Management Commentary: Management attributes revenue growth to volume increases and the consolidation of Greatbatch-Globe. They anticipate higher capital spending in 2003 to build out a new medical battery factory and invest in IT infrastructure.
- Liquidity: The company maintains $51.3 million in working capital and an unused $20 million credit line. Management believes historical cash generation is sufficient for operations and debt service, excluding acquisitions.
- Acquisitions: The company is actively discussing potential acquisitions but has no current commitments.
- Key Risks: Risks include dependence on a limited number of customers, product obsolescence, pricing pressure, reliance on third-party suppliers, and regulatory changes in the healthcare industry.
- Market Risk: A hypothetical 10% change in short-term interest rates could impact 2003 earnings by approximately $0.3 million.
Investor Verification Checklist
- Verify the sustainability of the 102% revenue growth in the Medical Components segment post-acquisition.
- Monitor the trend of gross margins, which declined despite revenue growth, to ensure cost integration of Greatbatch-Globe is effective.
- Assess the impact of the significant cash outflow ($2.4M decrease) on liquidity given the planned capital expenditures for the new factory.
- Review the terms of the new Battery Supply Agreement with Guidant Corporation (extended to 2006) for revenue stability.
- Confirm the company's ability to service its $79.5 million debt load while funding organic growth and potential future acquisitions.